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Abstract:  ʱ-Conotoxins  are  peptide  neurotoxins  isolated  from  venomous  marine  cone 
snails  that  are  potent  and  selective  antagonists  for  different  subtypes  of  nicotinic 
acetylcholine receptors (nAChRs). As such, they are valuable probes for dissecting the role 
that nAChRs play in nervous system function. In recent years, extensive insight into the 
binding mechanisms of ʱ-conotoxins with nAChRs at the molecular level has aided in the 
design  of  synthetic  analogs  with  improved  pharmacological  properties.  This  review 
examines  the  structure-activity  relationship  studies  involving  ʱ-conotoxins  as  research 
tools for studying nAChRs in the central and peripheral nervous systems and their use 
towards the development of novel therapeutics. 
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1. Introduction 
Since the pioneering work of Endean and colleagues, venoms from marine cone snails that inhabit 
tropical reef ecosystems have fascinated researchers due to their potent paralytic properties [1]. Given 
their  relatively  low  mobility  compared  to  other  aquatic  organisms,  cone  snails  have  evolved  an 
efficient biological strategy to rapidly immobilize their prey. Their venom is injected via an elaborate 
harpoon  mechanism,  which  utilizes  a  disposable  spear-like  radular  tooth  attached  to  a  retractable 
thread loaded with toxic venom such that upon contact, its prey is immediately subdued [2]. The rapid 
paralysis effected by cone snail venom is the result of a highly complex mixture of disulfide rich 
peptide  neurotoxins,  known  as  conotoxins  [3].  The  first  formal  characterization  of  conotoxins  by 
Olivera  and  co-workers  in  the  1980s  attracted  intense  interest  among  neuroscientists  and 
pharmacologists studying nervous system functions, by providing unique molecular probes and novel 
drug leads [4,5].  
In contrast to many other known marine natural products, which are complex organic compounds 
produced by the action of enzymes, conotoxins are peptides that are expressed as genetically encoded 
combinatorial libraries [6]. Conotoxin genes are active in the venom ducts of cone snails, where they 
are translated as a larger precursor peptide, which undergoes posttranslational processing to produce 
the mature active conotoxin [7]. Across the approximately 500 known cone snail species, it has been 
estimated  that  there  are  more  than  100,000  individual  conotoxins  with  unique  pharmacological 
properties [8]. Despite the complexity of cone snail venom, conotoxins have evolved from relatively 
few structural frameworks. Multiple disulfide bonds give rise to a series of intervening loops of amino 
acids, which contain a high degree of variability as a result of extensive mutation (i.e., hypermutation). 
Some of the major classes include ω-conotoxins (voltage gated calcium channels), δ- and μ-conotoxins 
(voltage  gated  sodium  channels),  χ-conotoxins  (norepinephrine  transporter),  ρ-conotoxins  
(ʱ1A-adrenoreceptor),  and  ʱ-conotoxins  (nicotinic  acetylcholine  receptors)  [9].  The  diversity  of  
ion-channels and receptors targeted by conotoxins makes them particularly useful research tools for 
studying the roles these receptors play in the central and peripheral nervous systems. Moreover, the 
therapeutic  potential  of  conotoxins  has  been  exemplified  though  the  development  of  the  calcium 
channel  blocker  Prialt
®  (ω-Conotoxin  MVIIA),  an  N-type  calcium  inhibitor  that  is  used  as  an 
intrathecal analgesic for the treatment of chronic neuropathic pain [10]. 
2. α-Conotoxins as Probes for Nicotinic Acetylcholine Receptors 
ʱ-Conotoxins  are  competitive  antagonists  of  nicotinic  acetylcholine  receptors  (nAChRs)  [11]. 
Nicotinic acetylcholine receptors belong to the superfamily of Cys-loop ligand-gated ion channels, 
which also includes 5-hydroxytryptamine, -aminobutyric acid (GABA), and glycine receptors [12]. 
Dysfunction  of nAChRs is implicated in several neuropathological conditions, including cognitive 
dysfunction, neuropathic pain, and nicotine reward mechanisms [13].  
Postsynaptic nAChRs are crucial mediators of the fast excitatory cholinergic neurotransmission in 
the  central  and  peripheral  nervous  systems,  which  also  influences  the  activity  in  several  other 
important neurotransmitter systems, including dopamine, glutamate, and GABA [14,15]. All nAChRs 
bind  the  neurotransmitter  acetylcholine,  which  induces  channel  opening  through  an  allosteric 
mechanism  [16].  Structurally,  nAChRs  are  pentameric  complexes  composed  of  combinations  of Toxins 2010, 2  
 
 
1473 
closely related ʱ1–10, 1–4, δ, and / subunits, each consisting of an extracellular ligand-binding 
domain, four transmembrane helices, and an extended intracellular region, symmetrically arranged 
around a central cation conducting pore. Muscle-type nAChRs exist at the skeletal neuromuscular 
junction, and are composed of two ʱ1-subunits and β1-, δ-, and /-subunits (ʱβδγ/ε) [17]. Neuronal 
nAChRs  are  either  heteromeric  combinations  of  ʱ2–6  and  β2–4-subunits,  ʱ9ʱ10  complexes,  or 
homomeric complexes consisting exclusively of ʱ7 or ʱ9 subunits [17]. The large number of different 
combinations of neuronal subunits gives rise to a large number of nAChR subtypes, each of which 
exhibits distinct neuropharmacological properties [18]. The different subtypes of nAChR subtypes are 
involved  in  a  range  of  neuropathological  conditions,  including  pain,  nicotine  addiction,  autism, 
epilepsy,  schizophrenia,  Tourette’s  syndrome,  Alzheimer’s,  and  Parkinson’s  diseases.  As  such, 
subtype specific ligands are profoundly important for studying the role that nAChRs play in such 
diseases to develop more effective therapeutic agents, with fewer side effects, than present options. 
The development of small molecule agonists based on the structures of nicotine, epibatidine, and 
cytisine  have  been  the  subject  of  numerous  drug  discovery  research  programs  for  developing 
therapeutics that target nAChRs (for review, see Jensen et al. [14] and Arneric et al. [19]). However, 
issues regarding receptor subtype selectivity remain a significant challenge. For example, Varenicline 
(Chantix
TM, Pfizer), which acts as a partial ʱ4β2 nAChR agonist, was approved by the FDA in 2006 to 
treat  nicotine  withdrawal  symptoms  [20].  Varenicline  has  been  shown  non-selective  for  the  ʱ4β2 
nAChR and has been shown to be a full agonist for the ʱ7 subtype [21]. Furthermore, recent reports 
indicate  that  Varenicline  may  be  associated  with  several  adverse  neuropsychiatric  side  effects, 
including depression and suicidal behavior [22,23].  
On  the  other  hand,  ʱ-conotoxins  exhibit  an  exquisite  ability  to  distinguish  between  different 
subtypes  of  nAChRs  [9].  They  are  competitive  antagonists  of  nAChRs  that  bind  at  the  interface 
between  ʱ-subunits  and  β-subunits  in  heteromeric  receptors,  and  between  two  ʱ-subunits  in 
homomeric receptors [17]. Their relative ease of chemical synthesis makes ʱ-conotoxins useful for 
probing nAChRs in the central and peripheral nervous system, with promising therapeutic potential for 
treating pain and other conditions [24]. Nonetheless, unlike most small molecule candidates, issues 
concerning the administration of conotoxins that limit their general applicability  as drugs need to  
be addressed. 
Typically,  ʱ-conotoxins  consist  of  between  12–20  amino  acid  residues  and  contain  two  highly 
conserved disulfide bonds (Table 1). In native ʱ-conotoxins, the disulfide bonds are connected in a 
(Cys
I-Cys
III),(Cys
II-Cys
IV) (globular) arrangement. Additional non-native isomers are also possible, 
namely the (Cys
I-Cys
IV),(Cys
II-Cys
III) (ribbon) and (Cys
I-Cys
II),(Cys
III-Cys
IV) (beads) isomers (Figure 1). 
The first and second cysteine residues are always adjacent, but the number of amino acid residues 
between the second and third cysteine, and between the third and fourth cysteine residues can vary. 
This gives rise to two loops of intervening amino acids denoted m and n, respectively. The cysteine 
framework refers to the number of residues in the m and n loops. For example, ʱ-conotoxins with a 4/7 
cysteine framework contain four and seven residues in their respective m and n loops. In addition to 
the intra-cysteine loops, some ʱ-conotoxins, including EI [25], GID [26], ArIA [27], SrIA [28], and 
PIA [29], have an extended N-terminal region which contains amino acids that are also important  
for activity. Toxins 2010, 2  
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Figure 1. Schematic diagram representing the three possible disulfide bond isomers of ʱ-conotoxins. 
 
ʱ-Conotoxins are among the most ubiquitous class of conotoxins identified so far, and the venom of 
nearly all Conus species is likely to contain at least one of these [30]. Furthermore, the number of  
ʱ-conotoxins that are being characterized is rapidly increasing, as new isolation techniques become 
available [31,32]. Interestingly, identical conotoxins have been identified from different cone snail 
species. For example, Lp1.1, first identified from cDNA libraries of Conus leopardus venom [33], has 
also been independently characterized from the venom of Conus litteratus (designated as LtIA) [34].  
Two  sub-classes  of  ʱ-conotoxins  are  able  to  discriminate  between  muscle  and  neuronal  type 
nAChRs [35]. Thus far, ʱ-conotoxins that target muscle nAChRs are predominantly found in  fish 
hunting species of cone snails [36], and additional sequences continue to be identified from cDNA 
libraries  [37].  While  muscle  specific  ʱ-conotoxins  generally  exhibit  a  3/5  cysteine  framework,  
ʱ-conotoxins EI and PIB are exceptions, exhibiting 4/7 and 4/4 frameworks, respectively [25,38].  
ʱ-Conotoxins GI, GIA, and GII were the first conotoxins to be biochemically characterized [5], and 
their features are consistent in all other muscle specific ʱ-conotoxins characterized to date, reflecting 
extensive  homology  among  this  class  [39–43].  Although  ʱ-conotoxin  SII  contains  one  additional 
disulfide bond outside of the regular cysteine framework, its overall sequence and loop structure are 
consistent with other ʱ-conotoxins [42].  
The second sub-class of ʱ-conotoxins has high specificity for neuronal nAChRs, and are among the 
most ubiquitous nAChR antagonists present in the venoms of fish, mollusk, and worm hunting cone 
snails  [30].  Although  more  than  half  of  the  known  ʱ-conotoxins  discovered  to  date  exhibit  a  
4/7-cysteine  framework,  other  neuronal  ʱ-conotoxins  possessing  unique  cysteine  frameworks  are 
continually being discovered, including 4/6 (AuIB) [44], 4/4 (BuIA) [45], and 4/3 (ImI, ImII and 
RgIA) [46–48]. Additionally, several ʱ-conotoxins possessing a 4/5 cysteine framework, including 
Ca1.1  and  Pu1.3,  have  been  identified  from  cDNA  libraries  [49,50].  Despite  the  occurrence  of 
different cysteine frameworks in nature, systematic truncation of the n-loop in synthetic analogs of  
ʱ-4/7-conotoxins  leads  to  significantly  decreased  conformational  stability  and  pharmacological 
activity [51]. 
Although their three-dimensional conformations are highly conserved, extensive mutation occurs 
within the ʱ-conotoxin m and n loops and small differences in amino acid side chains can lead to 
profound changes in receptor subtype specificity [11,52]. With a few exceptions, nearly all neuronal  
ʱ-conotoxins contain a conserved serine and proline residue in the m-loop (See Table 1). While not as 
prolific in ʱ-conotoxins as in some other conotoxin classes, posttranslational modifications have been Toxins 2010, 2  
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observed. Most ʱ-conotoxins exist as C-terminal carboxamides, although some exceptions, including 
SII and GID, exhibit a C-terminal carboxylate [26,42]. Other posttranslational modifications include 
carboxylation of glutamic acid to -carboxyglutamic acid and hydroxylation of proline [26,53,54]. 
Sulfonation of tyrosine has been observed in several ʱ-conotoxins, namely EpI, PnIA, PnIB, AnIA, 
AnIB, and AnIC [55–58]. Whereas incorporation of unsulfated tyrosine into ʱ-conotoxins PnIA and 
PnIA does not appear to significantly affect activity [56], the unsulfated forms of EpI, AnIA, and AnIA 
display moderate decreases in antagonist potency [57,59]. 
3. Structural Studies of α-Conotoxins 
Three-dimensional structural studies provide insight into the role of specific residues involved in 
nAChR binding and biological activity (Figure 2) [60]. Due to their comparatively small size and the 
associated  difficulties  in  crystallizing  ʱ-conotoxins,  relatively  few  X-ray  crystal  structures  of  
ʱ-conotoxins have been reported in the literature [61–63]. As such, NMR spectroscopy is usually the 
method of choice for calculating three-dimensional structural studies of ʱ-conotoxins and has been 
extensively conducted for many known ʱ-conotoxins and their synthetic analogs [64]. Nonetheless, 
three-dimensional structures  derived using both  methods  have  been  shown to exhibit very  similar 
conformations. Moreover, NMR structures acquired independently by different research groups under 
varying conditions, including differing solvent environments, appear to be in good agreement [65]. 
Figure 2. Three-dimensional structures of selected ʱ-conotoxins representing five different 
cysteine  frameworks.  (A)  X-ray  crystal  structure  of  ʱ3/5-GI  [61];  (B)  NMR  solution 
structure of ʱ4/3-ImI [66]; (C) NMR solution structure of ʱ4/4- BuIA [67]; (D) NMR 
solution  structure  of  ʱ4/6-AuIB  [68];  (E)  X-ray  crystal  structure  of  ʱ4/7-PnIA  [62]. 
Cysteine numbers and loop designations are indicated. 
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Table  1.  ʱ-Conotoxins  sequence  alignment  and  their  selectivity  for  nAChR  subtypes. 
Conserved  cysteine  residues  are  shaded  in  grey.  For  all  ʱ-conotoxins,  disulfide 
connectivity  is  between  Cys
I-Cys
III  and  Cys
II-Cys
IV.  The  conserved  proline  (or 
hydroxyproline) is boxed. Posttranslational modifications are defined as Z: pyroglutamate; 
Ø:  Hydroxyproline;  Ě:  γ-carboxyglutamate;  Ÿ:  sulfated  tyrosine;  *:  C-terminal  amide;  
^: C-terminal carboxylate. 
Name  Cysteine 
Framework 
Sequence 
m          n 
nAChR selectivity  Reference 
 
Ac1.1a 
3/5 
 NGRCC-HPACGKHFN--C*  ʱβδγ/ε  [35] 
Ac1.1b   NGRCC-HPACGKHSN--C*  ʱβδγ/ε  [35] 
CnIA    GRCC-HPACGKYYS--C*  ʱβδγ/ε  [41] 
CnIB      CC-HPACGKYYS--C*  ʱβδγ/ε  [41] 
GI     ECC-NPACGRHYS--C*  ʱβδγ/ε  [4] 
GIA     ECC-NPACGRHYS--CGK*  ʱβδγ/ε  [4] 
GII     ECC-NPACGKHFS--C*  ʱβδγ/ε  [4] 
MI    GRCC-HPACGKNYS--C*  ʱβδγ/ε  [37] 
SI     ICC-NPACGPKYS--C*  ʱβδγ/ε  [38] 
SIA     YCC-NPACGKNFD--C*  ʱβδγ/ε  [39] 
SII    GCCC-NPACGPNYG--CGTSCS^  ʱβδγ/ε  [40] 
ImI 
4/3 
   GCCSDPRCAWR----C*  ʱ7 ≈ ʱ3β2 > ʱ9ʱ10  [44] 
ImII     ACCSDRRCRWR----C*  ʱ7  [45] 
RgIA     GCCSDPRCRYR----CR^  ʱ9ʱ10 > 7  [46] 
BuIA 
4/4 
   GCCSTPPCAVLY---C*  ʱ6ʱ3β4  [43] 
PIB  ZSØGCCWNPACVKNR---C*  ʱβδγ/ε  [36] 
AuIB  4/6     GCCSYPPCFATNPD-C*  ʱ3β4  [42] 
AnIA 
4/7 
    CCSHPACAANNQDŸC*  ʱ3β2, ʱ7  [55] 
AnIB     GCCSHPACAANNQDŸC*  ʱ3β2, ʱ7  [55] 
ArIA  IRDECCSNPACRVNNPHVCRRR^  ʱ7 ≈ ʱ3β2  [25] 
ArIB    DECCSNPACRVNNPHVCRRR^  ʱ7 ≈ ʱ6β2 > ʱ3β2  [25] 
AuIA     GCCSYPPCFATNSDYC*  ʱ3β4  [42] 
AuIC     GCCSYPPCFATNSGYC*  ʱ3β4  [42] 
EI   RDØCCYHPTCNMSNPQIC*  ʱβδγ/ε  [23] 
EpI     GCCSDPRCNMNNPDŸC*  ʱ3β2/ʱ3β4  [53] 
GIC     GCCSHPACAGNNQHIC*  ʱ3β2 ≈ ʱ6β2 > ʱ7  [64] 
GID  IRDĚCCSNPACRVNNØHVC^  ʱ3β2  ʱ7 > ʱ4β2  [24] 
Lp1.1/LtIA     GCCARAACAGIHQELC*  ʱ3β2, ʱ6β2β3  [31,32] 
MII     GCCSNPVCHLEHSNLC*  ʱ3β2 ≈ ʱ6β2  [65] 
OmIA     GCCSHPACNVNNPHICG*  ʱ3β2 > ʱ7 > 623  [66] 
PIA   RDPCCSNPVCTVHNPQIC*  6/323  [27] 
PeIA     GCCSHPACSVNHPELC*  ʱ9ʱ10  [67] 
PnIA     GCCSLPPCAANNPDŸC*  ʱ3β2 > ʱ7  [68] 
PnIB     GCCSLPPCALSNPDŸC*  ʱ7 > ʱ3β2  [68] 
SrIA    RTCCSRØTCRMĚYPĚLCG*  ʱβδγ/ε  [26] 
SrIB    RTCCSRØTCRMEYPĚLCG*  ʱβδγ/ε  [26] 
TxIA     GCCSRPPCIANNPDLC*  ʱ3β2 > ʱ7  [69] 
Vc1.1     GCCSDPRCNYDHPEIC*  ʱ9ʱ10 > ʱ6β2 > ʱ3β2  ʱ3β4  [70] Toxins 2010, 2  
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Despite  their  relatively  small  size,  ʱ-conotoxins  adopt  very  well  defined  three-dimensional 
structures in solution that are stabilized by internal disulfide bonds, which are buried deep within the 
core of the molecule. They display a short 310 helical segment braced by the disulfide bond between 
Cys
I  and  Cys
III  that  comprises  the  active  portion  of  the  molecule  (Figure  2).  A  comparison  of  
ʱ-conotoxins with different numbers of residues in the  m-loop shows that their structures overlay 
across the n-loop [60]. However, there is often a clear difference in the conformation of the n-loop 
region, even among conotoxins possessing the same number of residues in this loop, suggesting the 
impact of hypervariablity on the structure and function of ʱ-conotoxins [60]. 
Another important conserved structural feature of ʱ-conotoxins is the presence of a proline residue 
in the m-loop, which exists in the trans conformation and is responsible for inducing the 310 helical 
turn  motif  that  orients  solvent  exposed  residues  towards  the  nAChR  binding  site  [65].  As  such, 
substitutions of proline with other ʱ-amino acids result in dramatic losses in nAChR activity, which 
can be attributed to a decrease in structural definition [47,76–80]. Nonetheless, novel conotoxins have 
been  discovered  that  do  not  include  a  conserved  proline,  including  ʱ-conotoxins  ImII  [47]  and 
Lp1.1/LtIA [33,34]. 
Misfolded disulfide bond isomers generally exhibit different 3D-conformations compared to native 
conotoxins, with the ribbon and beads isomers exhibiting greater conformational flexibility,  which 
often results in lower pharmacological activity [60,81]. However, the non-native ribbon isomer of  
ʱ-4/6-AuIB has been shown to exhibit 10-times more activity than the native conotoxin, suggesting a 
new  level  of  conotoxin  diversity  for  performing  structure-activity  relationship  studies  [82]. 
Interestingly,  the  globular  isomer  of  ʱ-4/4-BuIA  demonstrates  multiple  conformations  in  solution, 
including conformers distinct from the native ʱ-conotoxin folding motif [67]. 
While  NMR  spectroscopy  has  provided  much  valuable  structural  insight  into  ʱ-conotoxins,  an 
understanding of the structural basis of ʱ-conotoxin binding to nAChRs has increased considerably in 
recent years with the published X-ray co-crystal structures of acetylcholine-binding proteins (AChBPs) 
in complex with various ʱ-conotoxin ligands [83–85]. AChBPs are water soluble proteins isolated 
from  various  aquatic  snails,  and  X-ray  crystal  structures  of  AChBPs  from  Lymnaea  stagnalis  
(Ls-AChBP), Aplysia californica (Ac-AChBP), and Bulinus truncatus (Bt-AChBP) have been reported 
[86–88]. These proteins are expressed in molluskan glial cells and it has been proposed that their 
function is to modulate synaptic acetylcholine transmission [89]. AChBPs display sequence homology 
with the N-terminal ligand binding domain of several Cys-loop ligand-gated ion-channels, including 
nAChRs [12]. Moreover, they assemble into stable pentameric complexes characterized by binding 
affinities for nAChR ligands that are comparable to those exhibited by the homomeric ʱ7 nAChR [90]. 
AChBPs  are  very  useful  structural  surrogates  of  nAChRs  and  other  classes  of  ligand-gated  ion 
channels [91–93]. However, recently reported high-resolution X-ray crystal structures of ligand-gated 
ion channels promise to provide greater structural insight into nAChRs at the molecular level [94–97]. 
The relatively high degree of homology between nAChRs and AChBP provides the opportunity for 
computational  modeling  of  ʱ-conotoxin-receptor  interactions  [98].  Docking  of  ʱ-conotoxins  ImI, 
PnIA,  PnIB,  and  MII  into  ʱ7  and  ʱ32  nAChR  homology  models  derived  from  AChBP  crystal 
structures  reveals  insights  into  ʱ-conotoxin  binding  modes  at  these  receptors  [99].  These  studies 
indicate the ImI and PnIB binding site is located above the 9/10 hairpin of the ʱ7 nAChR subunit. 
Interestingly, PnIB, PnIA, and MII were found to bind in a similar location on ʱ7 or ʱ32 receptors, Toxins 2010, 2  
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predominantly  through  hydrophobic  interactions,  while  ImI  bound  further  from  the  ACh  binding 
pocket, mostly through electrostatic interactions. Other docking studies of RgIA have been reported 
using an ʱ9ʱ10 nAChR homology model derived from AChBP structures to reveal specific binding 
interactions [100].  
X-ray  co-crystal  structures  of  ʱ-conotoxins  ImI  and  PnIA[A10L,D14K]  bound  to  Ac-AChBP 
provide extensive detail into the binding interactions of ʱ-conotoxins with nAChRs and has allowed 
for  the  construction  of  more  reliable  homology  models  [83–85]. These  structures  show that  upon 
binding, ʱ-conotoxins are buried deep within the ligand binding site and interact with residues on both 
faces of adjacent subunits, with the toxin occupying all five binding sites of AChBP (Figure 3A) [85]. 
The toxin also opens the C-loop of AChBP and induces a rigid-body subunit movement (Figure 3B). 
Interestingly, AChBP does  not  induce any  structural  changes  in the bound conotoxin, with X-ray 
crystal structures of both free PnIA and bound PnIA[A10L,D14K] overlapping, suggesting that the  
ʱ-conotoxin  structural  framework  is  rigid,  and  binding  is  solely  determined  by  the  ability  of  the 
receptor to adapt to the conotoxin [85]. Another method for studying ʱ-conotoxin/ AChBP interactions 
involves saturation transfer difference NMR, which was been used to study complexes of Vc1.1 and 
MII bound to Ls-AChBP [101]. This study broadly highlights the utility of this approach by showing 
that aromatic residues present on the helical barrel of these ʱ-conotoxins (Tyr
10 of Vc1.1 and His
12 of 
MII) display strong interactions deep within the nicotinic binding site. 
Figure  3.  (A)  Top  view  of  the  X-ray  co-crystal  structure  of  ʱ-conotoxin 
PnIA[A10L,D14K] bound to Ac-AChBP (PDB ID: 2BR8) [83]. Each subunit is shown in a 
different  color  to  highlight  the  pentameric  arrangement  of  Ac-AChBP,  and  the  bound  
ʱ-conotoxin is shown in yellow; (B) Overlay of a single AChBP subunit with ʱ-conotoxin 
PnIA[A10L,D14K]  bound,  showing  an  open  C-loop  (cyan),  and  with  HEPES  bound, 
showing a closed C-loop (red). The ʱ-conotoxin in the open C-loop structure is shown in 
yellow (adapted from Celie et al. [85]). 
 
AChBPs have also proven to be useful tools in the discovery of new ʱ-conotoxins from cone snail 
venom  extracts,  with  the  discovery  of  -conotoxins  OmIA  and  TxIA  using  AChBP  competition 
binding assays [71,74]. Interestingly, nAChR ligands have been shown to display different binding Toxins 2010, 2  
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affinities for AChBPs from different species. For instance, ʱ-conotoxin ImI exhibits a 16,000-fold 
greater affinity for the Ac-AChBP over Ls-AChBP [87], while OmIA shows similar binding affinity 
for  AChBP  isolated  from  all  three  species  [71].  Similarly,  substitution  of  Asp
14  with  Lysine  in 
PnIA[A10L]  (PnIA[A10L,D14K])  resulted  in  an  analog  with  high  affinity  for  Ac-AChBP  and  
Ls-AChBP [85].  
4. Synthetic Mutants of α-Conotoxins 
Mutational analysis of the hypervariable regions of ʱ-conotoxins allow useful structure-activity 
relationships  to  be  elucidated.  As  such,  alanine  scanning  mutagenesis,  as  well  as  systematic 
replacement with other amino acid residues, allows one to determine the importance of function at 
each position. Generally, a significant change in activity for a mutated residue provides information on 
the importance of a given position in the conotoxin sequence. Such studies can reveal a great deal of 
information regarding pharmacophoric interactions of conotoxins with nAChRs (Figure 4). 
4.1. α-Conotoxins ImI and ImII 
ʱ-Conotoxin  ImI,  from  the  worm  hunting  cone  snail  Conus  imperialis,  was  the  first  neuronal  
ʱ-conotoxin to be discovered that displaced the ʱ7 nAChR selective snake toxin ʱ-bungarotoxin [46], 
however it was later shown that the toxin is also active at the ʱ3β2 subtype, and weakly active at the 
ʱ9ʱ10 subtype [102]. Nonetheless, given its relatively high selectivity and ease of chemical synthesis, 
ImI has been the subject for numerous structure-activity relationship studies. Alanine scanning of ImI 
indicated that Arg
7 plays a major role in ImI ʱ7 nAChR binding, with a significant decrease in activity 
observed  for  the  ImI[R7A]  analog  (Figure  4a)  [103].  Similarly,  ImI[P6A]  exhibited  a  profound 
decrease in activity, where this observation can be attributed to the loss of structural definition brought 
about by the conserved, conformationally restricted proline residue. Extensive NMR structural studies 
reveal  that  minor  conformational  changes  of  ImI  mutants  can  result  in  significantly  reduced 
pharmacological activity [104,105]. 
Several point mutations in ImI revealed its binding determinants to the ʱ7 nAChR. Substitution of 
the Arg
7 position with lysine was investigated, and despite maintaining the positive charge, resulted in 
significant losses in activity [76]. Similarly, substitution of Arg
7 with glutamine or glutamic acid also 
resulted in analogs with significantly lower activity, underlining the importance of this residue as a 
crucial determinant for ImI binding to ʱ7 nAChR [76]. While Arg
7 was originally believed to form 
important -cation interaction with conserved aromatic residues in the principle binding site of the 
receptor [99], it was later suggested, through homology modeling, that the positive charge of Arg
7 is 
stabilized by an intramolecular salt bridge in ImI, and van der Waals interactions with the receptor 
binding  site  [85].  Substitution  of  Trp
10  with  other  residues,  including  phenylalanine  and  tyrosine, 
resulted in analogs with similar activity to WT-ImI [76,106], indicating the importance of an aromatic 
side-chain residue at this position. Toxins 2010, 2  
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Figure 4. Summary of pharmacophore residues of selected -conotoxins, as determined by 
mutagenesis  studies.  Nonpolar  residues  are  shown  in  yellow;  polar  uncharged,  green; 
acidic, red; basic, blue. 
 
Close inspection of X-ray co-crystal structures of ʱ-conotoxin ImI bound to Ac-AChBP reveals that 
the  conserved  proline  in  these  conotoxins  is  oriented  towards  the  binding  pocket  of  endogenous 
ligands [83,84]. However, the conserved proline does not take part in any ligand/receptor interactions. 
Given that the conserved proline is important for maintaining the three-dimensional conformation of  
ʱ-conotoxins, a series of ʱ-conotoxin ImI derivatives were synthesized that incorporated substituted 
proline derivatives in position 6, resulting in several analogs with increased activity for the ʱ7 nAChR 
[107]. An ʱ7 nAChR homology model derived from Ac-AChBP reveals that a phenyl substituent in the 
5-R-position of Pro
6 in ImI leads to an efficient -stacking interaction with the binding site residues 
(Figure 5). However, the same substitution in PnIA[A10L] significantly decreased activity at the ʱ7 
nAChR [107]. Toxins 2010, 2  
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Figure  5.  Homology  model  of  ʱ-conotoxin  ImI-[Pro
6(5-R-phenyl)]  bound  to  the  ʱ7 
nAChR. Residues that form the binding pocket for endogenous ligands are indicated. The 
5-R-phenylproline residue is highlighted in green and each of the two subunits is indicated 
in orange and cyan, respectively. Adapted from Armishaw et al. [107]. 
 
ʱ-Conotoxin ImII, also isolated from Conus imperialis, is another potent ʱ7 nAChR antagonist 
[47]. Unlike ImI, ImII does not compete with  ʱ-bungarotoxin binding, which suggests a different 
binding site on the ʱ7 nAChR [102]. To characterize the binding mode of ImII in more detail, a series 
of ImII mutants were investigated by Tsetlin and co-workers, including ImII[W10Y] and the ribbon 
isomer of ImII [108]. Both isomers displaced [
125I]-ʱ-bungarotoxin from human ʱ7 nAChRs, as well as 
in Ac-AChBP and Ls-AChBP. On Torpedo nAChR, radiolabeled [
125I]-ImII[W10Y] revealed specific 
binding  and  was  readily  displaced  by  WT-ImII,  ImII[W10Y],  and  the  ImII  ribbon  isomer  [108]. 
However, a higher concentration of ImI was required to displace [
125I]-ImII[W10Y], thus providing 
further evidence for a distinct binding site for ImII. 
4.2. α-Conotoxins PnIA, PnIA and TxIA 
Two peptides isolated from the venom of the molluscivorous cone snail, Conus pennaceus, are  
-conotoxins PnIA and PnIB. Although they display very similar amino acid sequences, both were 
shown to target different nAChR subtypes (see Table 1) [73]. Two chimeric analogs were synthesized, 
resulting in a single amino acid substitution of PnIA at position 10 to leucine (PnIA[A10L]) and at 
position 11 to serine (PnIA[N11S]) to investigate the extent that each residue contributes to activity 
[109,110]. Interestingly, PnIA[A10L] demonstrated a complete switch in selectivity from ʱ32 to ʱ7 
nAChRs, while PnIA[N11S] showed reduced activity at both subtypes. Further alanine scanning of 
PnIA[A10L] indicates that residues between at position 15, and those between positions 5 and 13, 
were important for activity at the ʱ7 nAChR (Figure 4b) [111]. 
ʱ-Conotoxin  TxIA  was  discovered  from  crude  venom  extracts  of  Conus  textile  using  an  
[
125I]-ʱ-bungarotoxin binding assay against Ls-AChBP [74]. TxIA was shown to have a higher affinity 
for Ls-AChBP than any previously identified ʱ-conotoxin and is selective for ʱ32 nAChRs over the 
ʱ7 subtype. A comparison of the TxIA sequence with PnIA shows that these two conotoxins differ by Toxins 2010, 2  
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only  three  residues.  A  series  of  TxIA  mutants  suggested  that  long  chain  hydrophobic  residues  at 
positions 9 or 10 were important for activity, leading to the to TxIA[A10L] analog, which showed a 
greater  antagonistic  potency  for  the  ʱ7  nAChR  than  WT-TxIA.  An  X-ray  co-crystal  structure  of 
TxIA[A10L] with Ac-AChBP revealed a distinct binding orientation, with a 20 backbone tilt when 
compared  to  the  other  ʱ-conotoxin/AChBP  binding  complexes  [74].  Furthermore,  these  structural 
studies revealed an important salt bridge between Arg
5 of TxIA[A10L] and Asp
195 of AChBP. 
4.3. α-Conotoxin MII 
ʱ-Conotoxin MII was the first neuronal ʱ-conotoxin to be isolated from a fish hunting cone snail. 
Its features are typical of most other neuronal ʱ-conotoxins [70]. MII was first found to selectively 
inhibit the ʱ32 nAChR. However, later studies showed that it also blocks ʱ6-containing nAChRs 
[112]. Alanine scanning allowed the identification of Asn
5, Pro
6, and His
12 as major determinants for 
potency at the ʱ32 nAChR and ʱ6-containing subtypes (Figure 4c) [113]. The MII[E11A] analog was 
shown to increase selectivity for the ʱ62 and ʱ6ʱ42 subtypes [114,115]. Comparisons of the NMR 
structure of MII[E11A] suggest an increased hydrophobic area, relative to other ʱ-conotoxins, may be 
responsible for its selectivity for the ʱ62 nAChR [116]. The novel MII[S4A,E11A,L15A] analog was 
synthesized and allowed for the identification of amino acid residues in nAChR subunits that confer 
selectivity for ʱ3- and ʱ6 subunits [117]. The discovery of ʱ-conotoxin MII as an ʱ6-subunit nAChR 
antagonist has led to the characterization of additional ʱ-conotoxins that bind both ʱ32 and ʱ62 
nAChRs, including GIC [69], BuIA [45], PIA [29], and OmIA [71]. The binding of OmIA to various 
AChBPs  provides  a  unique  opportunity  for  developing  homology  models  of  ʱ6-containing  
nAChR subtypes. 
4.4. -Conotoxin GID 
ʱ-Conotoxin GID has been identified as an antagonist for the ʱ4β2 nAChR, although this conotoxin 
also blocks the ʱ7 and ʱ3β2 nAChR subtypes with a higher degree of potency [26]. Unlike most other 
ʱ-conotoxins,  GID  contains  a  C-terminal  carboxylate,  whereby  substitution  with  a  C-terminal 
carboxamide results in a loss of activity at the ʱ4β2 nAChR [118]. Another non-typical feature is the 
presence  of  arginine  at  position  12,  which  is  usually  a  hydrophobic  or  aromatic  residue  in  other  
ʱ-conotoxins. Given the therapeutic relevance of the ʱ4β2 nAChR in pain and nicotine addiction [17], 
GID  has  been  the  subject  of  mutagenesis  studies.  The  mutation  of  Arg
12  to  alanine  leads  to  a 
significant decrease in activity at the ʱ4β2 nAChR, but not the ʱ3β2 and ʱ7 nAChRs [26]. The Asn
14 
residue was also identified as being directly involved in interactions with the receptor [118].  
Even more significant is the presence of an N-terminal tail consisting of four amino acid residues 
that  contains  a  posttranslationally  modified  γ-carboxyglutamate  (Gla) residue at position 3.  While 
mutation of position 3 from Gla to glutamic acid in GID does not affect pharmacological activity, 
removal of the N-terminal tail leads to a significant decrease in antagonistic potency for the ʱ4β2 
nAChR [26]. However, the truncated peptide retains activity at ʱ7 and ʱ3β2 subtypes. This strongly 
suggests an important role for the N-terminal tail in receptor subtype selectivity. Despite this finding, 
an alanine scan of GID indicates that while all residues within the cysteine framework are necessary 
for binding to ʱ3β2 and ʱ7 nAChRs, specificity for the ʱ4β2 subtype is not necessarily limited to the Toxins 2010, 2  
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N-terminal tail, with Pro
9 playing an important role in maintaining the three-dimensional conformation 
of GID, as well as the roles of Arg
12 and Asn
14 in receptor binding interactions. 
4.5. α-Conotoxin ArIB 
ʱ-Conotoxin ArIB, which was isolated from cloning of Conus arenatus cDNA libraries, possesses 
the  same  extended  N-terminal  tail  as  GID  [27].  Although  the  predicted  sequence  contains  Glu  at 
position 3, it is possible that this residue is modified to Gla in the mature toxin. Through reference to 
previous mutagenesis studies of MII and PnIA, a series of directed substitutions in ArIB led to the 
synthesis of ArIB[V11L,V16D], which was found to be highly selective for the ʱ7 nAChR, and is the 
most selective ligand for this receptor reported to date [27]. Given the higher level of selectivity for the 
ʱ7 nAChR when compared to [
125I]-ʱ-bungarotoxin, a radiolabeled [
125I]-ArIB[V11L,V16D] analog 
was recently developed, and may find widespread use as a selective pharmacological probe [119]. 
4.6. -Conotoxins RgIA and Vc1.1 
Antagonists of the ʱ9ʱ10 nAChR are believed to be important targets for antinociceptive drugs that 
treat chronic neuropathic pain [120,121]. PeIA was the first ʱ-conotoxin shown to preferentially block 
the ʱ9ʱ10 nAChR over the ʱ7 nAChR [72]. Vc1.1 and RgIA show greater selectivity for the ʱ9ʱ10 
nAChR  than  PeIA  does  [122–125].  Both  of  Vc1.1  and  RgIA  been  shown  to  suppress  a  vascular 
response to pain in rats, which are involved in the transmission of pain [75]. While RgIA is the most 
selective  ʱ9ʱ10  nAChR  antagonist  identified  to  date,  Vc1.1  has  also  been  found  to  block  
ʱ6-containing subunits, as well as ʱ3-containing nAChRs with lower potency [120,125]. Both Vc1.1 
and RgIA target the ʱ9ʱ10 nAChR, although it has been proposed that Vc1.1 and RgIA also act as  
G-protein  coupled  GABAB  receptor  agonists  that  modulate  Cav2.2  channels,  resulting  in  their 
antinociceptive properties [126]. Vc1.1 has been shown to be an effective analgesic against pain in rat 
models following subcutaneous or intramuscular administration [122], and has been the subject for 
human clinical trials [24]. However, in vitro data indicated that Vc1.1 was ~100-fold less potent for 
human nAChRs compared to rat nAChRs, hence clinical development has been discontinued [124]. 
Intriguingly,  Vc1.1  and  RgIA  both  share  the  same  m-loop  sequence  (SDPR)  also  found  in  
ʱ-conotoxins  ImI  and  EpI,  which  are  more  selective  for  the  ʱ7  and  ʱ32  nAChR  subtypes, 
respectively. As such, selectivity for the ʱ9ʱ10 nAChR for Vc1.1 and RgIA is likely to be attributed to 
residues  in  the  n-loop.  Scanning  mutagenesis  of  Vc1.1  using  alanine,  aspartic  acid,  and  lysine, 
identified residues important for activity at the ʱ9ʱ10 nAChR as being Asp
5-Arg
7 and Asp
11-Ile
15 
(Figure 4d) [127]. Notably, several substitutions, in positions 4 and 9, were shown to be more potent at 
the  ʱ9ʱ10  nAChR  than  WT-Vc1.1  was.  A  second  generation  of  novel  mutants  was  synthesized, 
leading  to  the  identification  of  several  analogs  including  Vc1.1[N9G],  Vc1.1[N9I],  Vc1.1[N9L], 
Vc1.1[S4R], and Vc1.1[S4K,N9A] that were more potent and selective for the ʱ9ʱ10 nAChR than 
WT-Vc1.1 was [127].  
RgIA shares a very high degree of sequence homology with ImI, differing only in position 9 (Arg in 
RgIA; Ala in ImI) and position 10 (Tyr in RgIA; Trp in ImI), as well as the presence of an additional 
arginine  at  the  C-terminal  in  RgIA  (see  Table  1).  Side-chain  mutagenesis  of  the  RgIA  m-loop, 
including Asp
5, Pro
6 and Arg
7, were each shown to be crucial for inhibition of both the ʱ9ʱ10 and ʱ7 Toxins 2010, 2  
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subtypes [128]. Mutagenesis of the n-loop residues showed that RgIA[Y10W] exhibited near identical 
activity to the WT-RgIA, which was comparable to earlier mutagenesis studies involving ImI[W10Y], 
as  discussed  previously  [76].  Similarly,  the  absence  of  the  C-terminal  arginine  residue  had  no 
significant impact on activity. However, Arg
9 in the n-loop of RgIA was shown to be critical for 
specific binding to the ʱ9ʱ10 subtype. This can be attributed to the positively charged arginine side 
chain that directly interacts with the ʱ9ʱ10 nAChR, since WT-RgIA and RgIA[R9A] both exhibit 
identical backbone NMR structures [128]. 
5. High Throughput Synthesis of α-Conotoxin Analogs 
Preparation of ʱ-conotoxins by solid-phase peptide synthesis (SPPS) provides a rapid and facile 
route to significant quantities of native and modified material for use in structure-activity relationship 
studies  [129].  Despite  their  relative  ease  of  synthesis  and  the  vast  number  of  novel  ʱ-conotoxin 
analogs  prepared  to  date,  most  of  these  have  been  obtained  using  time  and  labor  intensive  
low-throughput synthetic methodology. Furthermore, the selective formation of disulfide bond isomers 
in large arrays of ʱ-conotoxin analogs remains a significant challenge [130]. While a large majority of 
mutagenesis studies of ʱ-conotoxins to date have primarily focused on single amino acid substitutions 
to obtain structure-activity relationships, the large number of possible amino acid combinations in  
ʱ-conotoxins makes the identification of active mutants “hit or miss”. As such, accelerated synthetic 
methodologies are required to rapidly identify ʱ-conotoxin analogs that selectively inhibit nAChRs 
and other novel pharmacological targets. 
A  high  throughput  synthetic  methodology  that  accelerates  production  of  conotoxins  has  been 
proposed, which promises access to a larger number of analogs in a shorter time frame than previously 
achievable [131]. Central to this methodology is the use of the safety catch amide linker (SCAL) [132], 
which allows simultaneous removal of side chain protecting groups and linker activation, followed by 
liberating  the  peptide  into  solution  by  reductive  amidolysis.  Disulfide  bonds  are  formed  
non-selectively  directly  from  the  cleavage  mixture  using  DMSO  oxidation,  resulting  in  varying 
mixtures  of  disulfide  bond  isomers.  A  regioselective  on-resin  supported  oxidation,  using 
selenocysteine, was recently reported. This oxidation allows regioselective formation of disulfide bond 
isomers  in  a  high-throughput  fashion  [133].  Although  the  use  of  SCAL  methodologies  has  been 
demonstrated for the high throughput production of conotoxin analogs,  its general applicability is 
limited by side reactions involving sensitive amino acid residues, particularly irreversible alkylation of 
tryptophan.  Nonetheless,  these  methodologies  will  no  doubt  find  useful  applications  in  the  high 
throughput production of ʱ-conotoxins. 
Mixture-based  combinatorial  methods  are  emerging  for  the  high  throughput  production  of  
ʱ-conotoxins  and  their  analogs  [134].  It  is  well  accepted  that  natural  product  extracts  provide  a 
valuable source of bioactive compounds with therapeutic relevance. Such extracts, including those 
from  Conus  venoms,  are  typically  composed  of  thousands  of  different  compounds  in  varying 
concentrations  [135].  On  the  other  hand,  synthetic  mixture-based  combinatorial  libraries  are 
systematically  arranged  mixtures  of  compounds  that  contain  every  possible  combination  of  the 
building  blocks  used  in  their  synthesis  [136].  Positional  scan  synthetic  combinatorial  libraries  
(PS-SCLs) provide a rapid means of acquiring functional information regarding all possible variable Toxins 2010, 2  
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positions  within  a  chemical  framework  [137].  As  such,  one  can  accurately  deconvolute  active 
sequences for a particular biological target from large mixtures of individual compounds that exist in 
very low concentrations in the assay sample.  
Although PS-SCLs have been used extensively by numerous researchers over the years for the 
successful discovery of high potency ligands for a wide range of biological targets [137–145], the use 
of this technique has been not been applied to conotoxins until recently. A synthetic combinatorial 
strategy for the high throughput production of ʱ-conotoxin ImI analogs broadly highlights the utility of 
PS-SCLs in ʱ-conotoxin structure-activity relationship studies, and allows for the design of potent and 
selective analogs [134]. Synthesis and pharmacological screening of a mixture based PS-SCL allowed 
amino acids that confer antagonistic activity to be identified. Significantly, three aromatic residues in 
position 10, tryptophan, tyrosine, and phenylalanine, were identified as being important for activity, 
which  is  consistent  with  results  from  previous  structure-activity  relationship  studies  [76,106]. 
Substitutions in position 9, including norleucine and leucine, as well as position 11, including histidine 
and  tryptophan,  were  identified,  prompting  the  synthesis  of  a  second  generation  of  individual  
ʱ-conotoxin analogs, which provided several analogs exhibiting improved antagonistic potency for the 
ʱ7 nAChR. A third generation of analogs was designed based on homology modeling studies using 
Ac-AChBP X-ray co-crystal structures to produce analogs with even greater antagonistic potencies by 
incorporation of other non-natural amino acid derivatives. A total of 96 individual ImI mutants were 
synthesized in high yield and purity, which is the largest number of reported ʱ-conotoxin analogs 
produced in a single study to date [134]. A drawback of using synthetic -conotoxin combinatorial 
libraries is the reliable folding of disulfide bonds  to the native disulfide bond isomer  in complex 
mixtures.  In  this  regard,  the  development  of  new  regioselective  on-resin  disulfide  bond  forming 
strategies may prove useful in overcoming this limitation [133]. 
Combinatorial  strategies  have  profound  potential  for  discovering  ʱ-conotoxins  with  novel 
pharmacological  activities.  For  example,  given  the  sequence  similarities  between  ImI  and  RgIA, 
screening of the ImI n-loop PS-SCL for activity at the ʱ9ʱ10 nAChR could potentially lead to highly 
potent and specific antagonists for this receptor. However, at the present time, screening of the large 
number  of  samples  generated  in  PS-SCLs  is  restricted  to  labor  intensive  electrophysiological 
recordings. Nonetheless, as more medium to high throughput screening assays become available for 
novel nAChR receptor subtypes, combinatorial libraries of ʱ-conotoxins would be expected to be used 
more widely in structure-activity relationship studies and in the development of potent and specific 
nAChR ligands, as well as of ligands for other classes of ion channels and receptors. 
6. Novel α-Conotoxin Analogs with Enhanced Pharmacokinetic Properties 
Despite the therapeutic potential of ʱ-conotoxins, the issue of in vivo stability and bioavailability 
remains a significant limitation. As with other classes of bioactive peptides, ʱ-conotoxins generally 
exhibit poor in vivo stability, due to their susceptibility to degradation by endo- and exoproteases. 
Furthermore,  issues  regarding  bioavailability  and  membrane  permeability  limit  the  general 
applicability  of  conotoxins  as  drugs.  As  such,  much  effort  has  focused  on  improving  the 
pharmacokinetic  properties  of  -conotoxins  while  maintaining  their  potency  and  selectivity  for 
nAChR subtypes. Toxins 2010, 2  
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It is well known that N-to-C cyclic peptides exhibit improved stability in vivo over linear peptides 
and have more restricted conformations [146]. Given the potential of ʱ-conotoxins as in vivo research 
tools and drug leads, a valuable approach to improving their physical stability is to link their N- and C- 
termini. This approach has been successfully investigated and used for preparing stable and potent 
analogs of ʱ-conotoxin MII [147]. Importantly, the spatial relationship between the N- and C-termini 
must be maintained, hence an oligopeptide spacer unit is required to preserve the three-dimensional 
conformation  of  the  native  ʱ-conotoxin.  When  an  appropriate  spacer  length  was  utilized,  cyclic 
analogs of MII were shown to exhibit greatly improved stability over the native peptides, yet their 
three-dimensional structure and pharmacological activity were retained. This strategy has also been 
successfully  applied  to  the  synthesis  of  cyclic  χ-conotoxin  MrIA  analogs  [148].  Recently,  it  was 
reported that cyclization of ʱ-conotoxin ImI led to the preferential formation of the ribbon disulfide 
bond  isomer,  particularly  when  a  shorter  oligopeptide  spacer  length  was  selected  [149].  As  such, 
regioselective disulfide bond formation was required to obtain the native globular isomer, and it was 
shown  that  cyclic  globular  analogs  of  ImI  exhibited  superior  stability  compared  to  cyclic  ribbon 
analogs, which demonstrated comparable stability to WT-ImI. 
Peptides, in general, do not pass easily though biological membranes, such as the gastrointestinal 
tract and the blood-brain barrier. As such, the issues of membrane permeability and oral availability 
have also been explored. Incorporation of a lipidic amino acid (Laa), 2-amino-D,L-dodecanoic acid 
into MII at the N-terminal, as well as substitution of Asn
 at position 5 was shown to significantly 
improve permeability across Caco-2 cell monolayers for both analogs, while maintaining inhibitory 
potency  at  the  ʱ3β2  nAChR  [150].  Furthermore,  NMR  analysis  revealed  both  Laa-MII  analogs 
possessed  a  similar  structure  to  WT-MII.  An  in  vivo  biodistribution  study  following  oral 
administration of Laa-MII analogs in rats showed that although uptake was not significantly enhanced, 
the compounds did pass through the gastrointestinal tract, as suggested by increased accumulation of 
the compounds in the liver [151]. However, neither Laa-MII analog crossed the blood-brain barrier, 
underlining the importance of further investigation into developing novel ʱ-conotoxin analogs that can 
permeate  biological  membranes.  A  cyclic  χ-conotoxin  MrIA  has  been  reported  where  Laa’s  were 
attached  to  the  oligopeptide  spacer  unit  and  exhibited  comparable  activity  to  WT-MrIA  [152], 
although biodistribution studies of these analogs are yet to be performed to assess their permeability 
across the blood-brain barrier. 
Another concern with ʱ-conotoxins as drugs is that their disulfide bond frameworks are susceptible 
to scrambling to other isomers under physiological conditions. To address this issue, replacement of 
the disulfide bond framework with non-reducible disulfide mimetics has been investigated by several 
groups  (Figure  6).  Lactam  bridges  were  initially  investigated  by  Barany  and  coworkers  using  
ʱ-conotoxin SI as a model (Figure 6a) [153]. Systematic replacement of the Cys
2-Cys
7 disulfide bond 
with a lactam bridge in two orientations resulted in complete loss of activity at muscle type nAChRs. 
However, replacement of the Cys
3-Cys
13 disulfide bond resulted in ~70-fold increase in affinity for 
one lactam orientation. A synthetic analog of ʱ-conotoxin GI that substituted both disulfide bonds with 
a thioether mimetic has been investigated to improve the stability of conotoxins (Figure 6b). However, 
these analogs resulted in profound decreases in pharmacological activity [154]. The changes in activity 
for both studies can be directly attributed to differences in the bond geometry between disulfide bonds 
and these mimetics. Toxins 2010, 2  
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Figure 6. Non reducible disulfide mimetics that have been incorporated into ʱ-conotoxin 
analogs. (a) lactam; (b) thioether; (c) dicarba; and (d) diselenide bridges. 
 
Dicarba-linkages  more  closely  resemble  the  bond  geometry  of  disulfide  bonds,  and  have  been 
successfully incorporated in ʱ-conotoxin ImI, resulting in analogs with improved stability (Figure 6c) 
[155]. Cysteine residues at positions 2 and 8 were substituted with allylglycine, followed by on-resin 
microwave assisted ring-closing metathesis. The dicarba-ImI analog was shown to exhibit very similar 
antagonistic  properties  ʱ7  nAChRs  compared  to  WT-ImI  in  two  different  functional  assays. 
Structurally, the NMR solution structure of the dicarba-ImI analog was very similar to the reported 
structure  for  WT-ImI.  Nonetheless,  minor  structural  differences  were  attributed  to  the  different 
covalent geometry of the dicarba moiety compared to a disulfide bond, since the carbon-carbon double 
bond is significantly shorter than a corresponding sulfur-sulfur bond. 
A  more  conservative  disulfide  bond  isostere,  the  diselenide  bond,  has  been  shown  to  enhance 
disulfide bond stability under reducing conditions and is a convenient folding tool for synthesizing  
ʱ-conotoxins (Figure 6d) [133,156], as well as other more complex conotoxin frameworks [157,158]. 
Selenocysteine (Sec) is a naturally occurring amino acid, which forms an essential catalytic group in 
several redox enzymes. It exhibits the propensity to oxidatively form a diselenide bond analogous to 
the disulfide bond and exhibits very similar bond geometry  [159]. However, selenocysteine has a 
higher oxidation potential than cysteine, which allows it to be selectively oxidized over cysteine under 
very mild conditions [160].  
A series of ʱ-conotoxin ImI analogs, termed “ʱ-selenoconotoxins” were synthesized by solid phase 
peptide synthesis with complementary replacement of either one ([Sec2,8]-ImI or [Sec3,12]-ImI), or 
both  ([Sec2,3,8,12]-ImI)  disulfide  bonds  with  diselenide  bonds  [156].  Each  analog  demonstrated 
remarkable stability to reduction or scrambling under a range of chemical and biological reducing 
conditions, such as blood plasma thiols. Three-dimensional structural characterization by NMR and 
CD spectroscopy indicated conformational preferences that were very similar to native ImI, suggesting 
fully isomorphic structures. Additionally, full bioactivity was retained at the ʱ7 nAChR, with each  
ʱ-selenoconotoxin  exhibiting  a  dose  response  curve  that  overlaps  with  WT-ImI.  This  work 
demonstrated  that  selenoconotoxins  can  be  used  as  highly  stable  scaffolds  for  the  design  of  new 
conotoxin based drugs. Recently, ʱ-conotoxins representing five different cysteine frameworks were 
synthesized using SCAL methodology, demonstrating exclusive formation of the native disulfide bond 
isomers in all cases [133]. As was shown in previous studies, the ʱ-selenoconotoxins exhibited similar 
antagonist potency for nAChR subtypes, with improved stability in human blood plasma. Furthermore, 
the  X-ray  crystal  structure  of  ʱ-selenoconotoxin  PnIA  demonstrated  a  fully  conserved  fold  when 
compared to native PnIA. These studies highlight the utility of selenocysteine technology to high 
throughput ʱ-conotoxin synthesis, since successive isolation steps are not required following cleavage. Toxins 2010, 2  
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7. Conclusions and Future Perspectives 
The chemical synthesis of ʱ-conotoxins for use in structure-activity relationship studies has led to 
the development of novel analogs that can be used as valuable research tools for studying the roles that 
nAChRs play in various neuropathological disorders and disease states. Furthermore, X-ray crystal 
structures of ʱ-conotoxin/acetylcholine binding protein complexes permit more accurate homology 
models of nAChRs to be developed, allowing for the rational design of novel analogs with refined 
pharmacological properties. However, high-throughput synthetic methods and combinatorial strategies 
promise to greatly accelerate the identification of ʱ-conotoxin analogs that are selective for nAChR 
subtypes,  and  other  novel  pharmacological  targets.  Despite  their  promising  therapeutic  potential, 
improving the pharmacokinetic properties of ʱ-conotoxins remains an issue that needs to be addressed. 
Nevertheless,  new  strategies  for  improving  the  in  vivo  stability  and  membrane  permeability  of  
ʱ-conotoxins  continue  to  be  investigated  by  various  research  groups  toward  the  development  of  
ʱ-conotoxins as novel therapeutics.  
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